Pulse Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Pulse Biosciences, Inc. on June 11, 2026. The meeting was conducted virtually via live audio webcast.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Election of Directors: Seven nominees were elected to serve until the 2027 Annual Meeting. All nominees received significant majority support, with "For" votes ranging from approximately 33.4 million to 35.0 million. "Against" votes ranged from approximately 18,000 to 1.6 million per nominee.
- Ratification of Auditors: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 45,976,355 votes "For" and 8,265 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that all seven director nominees were successfully elected.
- Verification that Deloitte & Touche LLP is the appointed auditor for the fiscal year ending December 31, 2026.
- Review of the specific vote counts to assess shareholder sentiment, noting that while all directors were elected, some received over 1.5 million "Against" votes.